The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase
Background: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS). T...
Main Authors: | Yanghee Woo, Susanne G Warner, Rula Geha, Marianne M Stanford, Penelope Decarolis, Masmudur M Rahman, Samuel Singer, Grant McFadden, Yuman Fong |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.1177/1179554921993069 |
Similar Items
-
Oncolytic Virotherapy with Myxoma Virus
by: Masmudur M. Rahman, et al.
Published: (2020-01-01) -
Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
by: Amy L. MacNeill, et al.
Published: (2018-07-01) -
Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
by: Joanna Jazowiecka-Rakus, et al.
Published: (2020-09-01) -
Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
by: Masmudur M. Rahman, et al.
Published: (2020-05-01) -
Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN‐Induced Antiviral State in a Highly Species‐Specific Fashion
by: Masmudur M. Rahman, et al.
Published: (2017-02-01)